• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

VHL 基因突变在 CCRCC 中并不决定 HIF、CAIX、hnRNP A2/B1 和骨桥蛋白的失调。

VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.

机构信息

Leslie C. Quick Laboratory, Cork Cancer Research Centre, BioSciences Institute, University College Cork, Ireland.

出版信息

Cell Oncol (Dordr). 2011 Jun;34(3):225-34. doi: 10.1007/s13402-011-0029-5. Epub 2011 May 6.

DOI:10.1007/s13402-011-0029-5
PMID:21547579
Abstract

BACKGROUND

Von Hippel-Lindau (VHL) tumour suppressor gene inactivation is associated with clear cell renal cell carcinoma (CCRCC) development. The VHL protein (pVHL) has been proposed to regulate the expression of several proteins including Hypoxia Inducible Factor-α (HIF-α), carbonic anhydrase (CA)IX, heterogeneous nuclear ribonucleoprotein (hnRNP)A2/B1 and osteopontin. pVHL has been characterized in vitro, however, clinical studies are limited. We evaluated the impact of VHL genetic alterations on the expression of several pVHL protein targets in paired normal and tumor tissue.

METHODS

The VHL gene was sequenced in 23 CCRCC patients and VHL transcript levels were evaluated by Real-Time RT-PCR. Expression of pVHL's protein targets were determined by Western blotting in 17 paired patient samples.

RESULTS

VHL genetic alterations were identified in 43.5% (10/23) of CCRCCs. HIF-1α, HIF-2α and CAIX were up-regulated in 88.2% (15/17), 100% (17/17) and 88.2% (15/17) of tumors respectively and their expression is independent of VHL status. hnRNP A2/B1 and osteopontin expression was variable in CCRCCs and had no association with VHL genetic status.

CONCLUSION

As expression of these proposed pVHL targets can be achieved independently of VHL mutation (and possibly by hypoxia alone), this data suggests that other pVHL targets may be more crucial in renal carcinogenesis.

摘要

背景

冯·希佩尔-林道(VHL)肿瘤抑制基因失活与肾透明细胞癌(CCRCC)的发生有关。VHL 蛋白(pVHL)被认为可以调节多种蛋白的表达,包括缺氧诱导因子-α(HIF-α)、碳酸酐酶(CA)IX、异质核核糖核蛋白(hnRNP)A2/B1 和骨桥蛋白。虽然已经在体外对 pVHL 进行了表征,但临床研究有限。我们评估了 VHL 基因突变对配对正常和肿瘤组织中几种 pVHL 蛋白靶标表达的影响。

方法

对 23 例 CCRCC 患者进行了 VHL 基因测序,并通过实时 RT-PCR 评估了 VHL 转录水平。在 17 对配对患者样本中通过 Western blot 检测了 pVHL 蛋白靶标的表达。

结果

在 43.5%(10/23)的 CCRCC 中发现了 VHL 基因突变。HIF-1α、HIF-2α 和 CAIX 在 88.2%(15/17)、100%(17/17)和 88.2%(15/17)的肿瘤中上调,其表达独立于 VHL 状态。hnRNP A2/B1 和骨桥蛋白在 CCRCC 中的表达是可变的,与 VHL 遗传状态无关。

结论

由于这些提议的 pVHL 靶标的表达可以独立于 VHL 突变(可能仅通过缺氧)实现,因此这表明其他 pVHL 靶标在肾发生过程中可能更为重要。

相似文献

1
VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.VHL 基因突变在 CCRCC 中并不决定 HIF、CAIX、hnRNP A2/B1 和骨桥蛋白的失调。
Cell Oncol (Dordr). 2011 Jun;34(3):225-34. doi: 10.1007/s13402-011-0029-5. Epub 2011 May 6.
2
VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.VHL 基因突变在 CCRCC 中并不决定 HIF、CAIX、hnRNP A2/B1 和骨桥蛋白的失调。
Anal Cell Pathol (Amst). 2010;33(3):121-32. doi: 10.3233/ACP-CLO-2010-0541.
3
Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.结节性硬化症复合物蛋白1的表达受散发性透明细胞肾细胞癌中VHL基因改变和HIF-1α产生的影响。
Exp Mol Pathol. 2016 Dec;101(3):323-331. doi: 10.1016/j.yexmp.2016.11.003. Epub 2016 Nov 12.
4
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.缺氧、缺氧诱导转录因子与肾癌
Eur Urol. 2016 Apr;69(4):646-657. doi: 10.1016/j.eururo.2015.08.007. Epub 2015 Aug 19.
5
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.蛋白酪氨酸磷酸酶受体 J 型受透明细胞肾细胞癌中 pVHL-HIF 轴的调控。
J Pathol. 2013 Mar;229(4):525-34. doi: 10.1002/path.4107. Epub 2013 Jan 21.
6
The VHL-dependent regulation of microRNAs in renal cancer.VHL 依赖性调控肾癌中的 microRNAs。
BMC Med. 2010 Oct 21;8:64. doi: 10.1186/1741-7015-8-64.
7
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.在透明细胞肾细胞癌中,HIF-1α 对碳酸酐酶IX(CAIX,G250/MN)的严格调控。
Oncogene. 2004 Jul 22;23(33):5624-31. doi: 10.1038/sj.onc.1207764.
8
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.硒通过脯氨酰羟化酶 2 依赖性和 von Hippel-Lindau 非依赖性降解,抑制肾透明细胞癌细胞中低氧诱导因子 1 和 2α,从而抑制肿瘤生长。
BMC Cancer. 2012 Jul 17;12:293. doi: 10.1186/1471-2407-12-293.
9
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.von Hippel-Lindau 肿瘤抑制蛋白通过组蛋白去甲基酶 JARID1C 调节基因表达和肿瘤生长。
Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.
10
Identification of novel VHL target genes and relationship to hypoxic response pathways.新型VHL靶基因的鉴定及其与缺氧反应途径的关系。
Oncogene. 2005 Jun 30;24(28):4549-58. doi: 10.1038/sj.onc.1208649.

引用本文的文献

1
Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.VHL、HIF1A、HIF2A、VEGFA 和 p53 表达对接受舒尼替尼一线治疗的透明细胞肾细胞癌患者的预后意义。
Int J Oncol. 2019 Aug;55(2):371-390. doi: 10.3892/ijo.2019.4830. Epub 2019 Jun 25.
2
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.(18)F-VM4-037 正电子发射断层扫描/计算机断层扫描成像在肾细胞癌中的应用:一项 II 期先导研究。
Abdom Radiol (NY). 2016 Jan;41(1):109-18. doi: 10.1007/s00261-015-0599-1.
3
The role of HIF1α in renal cell carcinoma tumorigenesis.

本文引用的文献

1
Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.低级别和高级别散发性透明细胞肾细胞癌中不同的血管生成潜能与冯·希佩尔-林道基因的改变无关。
Cell Oncol. 2009;31(5):371-82. doi: 10.3233/CLO-2009-0482.
2
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.缺氧诱导因子-α对c-Myc的影响区分了散发性VHL基因缺陷型透明细胞肾细胞癌的两种亚型。
Cancer Cell. 2008 Dec 9;14(6):435-46. doi: 10.1016/j.ccr.2008.10.016.
3
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.
缺氧诱导因子1α(HIF1α)在肾细胞癌肿瘤发生中的作用。
J Mol Med (Berl). 2014 Aug;92(8):825-36. doi: 10.1007/s00109-014-1180-z. Epub 2014 Jun 12.
4
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者对舒尼替尼反应的潜在预测标志物和生存数据分析。
PLoS One. 2013 Sep 27;8(9):e76386. doi: 10.1371/journal.pone.0076386. eCollection 2013.
冯·希佩尔-林道肿瘤抑制蛋白:氧感知与癌症
Nat Rev Cancer. 2008 Nov;8(11):865-73. doi: 10.1038/nrc2502. Epub 2008 Oct 16.
4
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.pVHL和PTEN肿瘤抑制蛋白协同抑制肾囊肿形成。
EMBO J. 2008 Jun 18;27(12):1747-57. doi: 10.1038/emboj.2008.96. Epub 2008 May 22.
5
Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.VHL(冯·希佩尔-林道)基因在肾癌中的作用:一种多功能肿瘤抑制基因。
Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8. doi: 10.1042/BST0360472.
6
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.低碳酸酐酶IX(CAIX)表达及VHL基因突变缺失与透明细胞肾细胞癌的肿瘤侵袭性及不良预后相关。
Int J Cancer. 2008 Jul 15;123(2):395-400. doi: 10.1002/ijc.23496.
7
The role of hypoxia-inducible factors in tumorigenesis.缺氧诱导因子在肿瘤发生中的作用。
Cell Death Differ. 2008 Apr;15(4):678-85. doi: 10.1038/cdd.2008.21. Epub 2008 Feb 15.
8
The VHL tumor suppressor and HIF: insights from genetic studies in mice.VHL肿瘤抑制因子与缺氧诱导因子:来自小鼠遗传学研究的见解
Cell Death Differ. 2008 Apr;15(4):650-9. doi: 10.1038/sj.cdd.4402313. Epub 2008 Jan 25.
9
Renal cell carcinoma: current status and emerging therapies.肾细胞癌:现状与新兴疗法
Cancer Treat Rev. 2007 May;33(3):299-313. doi: 10.1016/j.ctrv.2006.12.005. Epub 2007 Feb 27.
10
The role of carbonic anhydrases in renal physiology.碳酸酐酶在肾脏生理学中的作用。
Kidney Int. 2007 Jan;71(2):103-15. doi: 10.1038/sj.ki.5002020. Epub 2006 Dec 13.